



Published in final edited form as:

J Nat Prod. 2010 October 22; 73(10): 1694–1700. doi:10.1021/np100461t.

Bioactive Cycloperoxides Isolated from the Puerto Rican Sponge *Plakortis halichondrioides*

Carlos Jiménez-Romero[†], Idelisse Ortiz[†], Jan Vicente[†], Brunilda Vera[†], Abimael D. Rodríguez^{*†}, Sangkil Nam[‡], and Richard Jove[‡]

Department of Chemistry, University of Puerto Rico, P.O. Box 23346, U.P.R. Station, San Juan, Puerto Rico 00931-3346, and Department of Molecular Medicine, Beckman Research Institute, City of Hope, 500 East Duarte Road, Duarte, California 91010

[†]Department of Chemistry, University of Puerto Rico

[‡]Department of Molecular Medicine, Beckman Research Institute, City of Hope

Abstract

Two new five-membered ring polyketide endoperoxides, epiplakinic acid F methyl ester (**1**) and epiplakinidioic acid (**3**), and a peroxide–lactone, plakortolide J (**2**), were isolated from the Puerto Rican sponge *Plakortis halichondrioides*, along with two previously reported cyclic peroxides, **4** and **5**. The structures of the new metabolites were determined by spectroscopic and chemical analyses. The absolute stereostructures of **1**, **2**, and **5** were determined by degradation reactions followed by application of Kishi's method for the assignment of absolute configuration of alcohols. Biological screening of cycloperoxides **1–5** and semisynthetic analogs **7–12** for cytotoxic activity against various human tumor cell lines revealed that compounds **3**, **4** and **11** are very active. Upon assaying for antimalarial and antitubercular activity, some of the compounds tested showed strong activity against the pathogenic microbes *Plasmodium falciparum* and *Mycobacterium tuberculosis*.

Marine sponges of the family Plakinidae have been reported to be a rich source of cyclic peroxides, many of which often exhibit antimicrobial, ichthyotoxic, antineuroinflammatory, and antitumor properties.¹ Recently, a number of such bioactive polyketides have also been shown to be active against the protozoan parasites *Plasmodium falciparum*, *Leishmania chagasi*, *Trypanosoma brucei brucei*, and *Trypanosoma cruzi*.² Many of these interesting natural products either contain a six-membered (1,2-dioxane) or a five-membered (1,2-dioxolane) peroxide ring.³ Representative examples of these groups of secondary metabolites, most of which have been isolated from sponges belonging to the two taxonomically-related genera *Plakinastrella* and *Plakortis*, include the plakinic acid and the plakortolide series of cyclic peroxides.^{4,5} Already in 2003, we reported two strongly cytotoxic 1,2-dioxanes, plakortide O and plakortide P, from the Caribbean marine sponge

^{*}To whom correspondence should be addressed. Tel: (787)-764-0000 Ext. 4799, Fax: (787)-756-8242. abrodriguez@uprrp.edu.

Supporting Information Available: An underwater photograph of *Plakortis halichondrioides* and copies of the ¹H NMR, ¹³C NMR, HSQC, HMBC, NOESY, and MS spectra of cycloperoxides **1**, **2**, and **6**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Plakortis halichondrioides (Wilson, 1902).⁶ Since that investigation, we have isolated three new endoperoxides from a recently re-collected sponge specimen using a bioassay-guided purification protocol. The first two compounds, trivially named epiplakinic acid F methyl ester (**1**) and plakortolide J (**2**), contain a conjugated triene along an unbranched C₁₆ alkyl side chain. The least abundant of these metabolites, epiplakinidioic acid (**3**), is a rare dicarboxylic acid derivative with a shortened side chain compared to compounds **1** and **2**. In this account, we report the isolation, structure determination, and biological evaluation of these natural products and those of several semisynthetic analogs.

Results and Discussion

A freeze-dried specimen of the sponge *P. halichondrioides* (395 g) was extracted with a 1:1 mixture of CHCl₃–CH₃OH, and after concentration the organic extract was partitioned between *n*-hexane and water. Significant antitumor activity was detected in the *n*-hexane extract (16.4 g); upon treatment with 1.0 mg/mL extract, reduction of cell viability was 70, 90, and 92% for DU-145 prostate cancer, A2058 melanoma, and MDA-MB-435 breast cancer cells, respectively. Subsequent analysis of this material by ¹H and ¹³C NMR indicated the presence of polyketides; therefore a small portion of the *n*-hexane extract was subjected to Si gel flash chromatography. Only those compounds that eluted with mixtures of *n*-hexane–acetone of increasing polarity displaying >30% cells viability were investigated further. Additional separation steps of the active fractions by normal–phase column chromatography led to the isolation of new polyketide derivatives epiplakinic acid F methyl ester (**1**), plakortolide J (**2**), and epiplakinidioic acid (**3**), as well as the known polyketides epiplakinic acid F (**4**) and plakortolide F (**5**). As optical rotation data were lacking, identification of known compounds **4** and **5** was based exclusively on comparison of their spectroscopic properties (IR, MS, and NMR) with values already described in the literature.^{4d,7}

The ¹³C NMR spectrum and HREIMS data for **1** suggested a molecular formula of C₂₄H₄₀O₄. Inspection of the NMR spectra suggested that the compound was closely related to epiplakinic acid F (**4**) reported by Wright in 2001 from a *Plakinastrella* sponge species from the Seychelle Islands.^{4d} A comparison of the NMR data of **1** (Table 1) with those of **4** quickly showed that **1** has the same 1,2-dioxolane ring (with *trans*-oriented methyl substituents at the C3 and C5 positions) and the same unbranched C₁₆ alkyl chain (including assignment of geometry of the ¹⁴, ¹⁶, and ¹⁸ double bonds) of **4**. Thus, the only difference between both compounds arises from the replacement of the carboxylic acid moiety at C2 in **4** by a methylcarboxylate group in **1**. Methylation of **4** at 25 °C with diazomethane in ether yielded an inseparable mixture of compounds, the major one of which was shown to be ester **1** by comparison of ¹H NMR spectra. Compound **1**, however, was extremely unstable, decomposing in the presence of air over varying periods of time, to carboxylic acid **6**, which was devoid of significant biological activity.⁸ The co-isolation of **1** and **4** from the same organism raises the possibility that the former compound is an isolation artifact due to the extraction with MeOH.

As the absolute stereostructure of epiplakinic acid F (**4**) was not determined during the 2001 investigation, we established the absolute configuration from its methyl ester **1** by reductive

cleavage of the peroxide ring with H₂ and 10% Pd/C in EtOAc to afford the diol-ester derivative **8** and a small amount of the separable peroxide-ester derivative **7** (Scheme 1). The former intermediate, obtained in 29% isolated yield, was intramolecularly transesterified to δ -lactone **9**. Upon analysis of the ¹³C NMR chemical shifts of the carbons in **9** adjacent to the tertiary alcoholic center in the presence of chiral lanthanide shift reagents, as described by Kishi *et al.*,⁹ the absolute configuration at C-3 was found to be *S* (Table 2). Coupled with the relative geometry derived from the above analyses, this established the absolute configuration of the peroxide ring in compound **1** as *3S, 5R*.

Plakortolide J [(**2**), (*3S,4S,6S,15E,17E,19E*)-4,6-dimethyl-4-hydroxy-3,6-peroxy-docosa-15,17,19-trienoic acid 1,4-lactone] was isolated as an extremely unstable colorless oil, which rendered its purification and characterization difficult. The molecular formula of C₂₄H₃₈O₄, which requires six degrees of unsaturation, was established from HREIMS. The IR spectrum showed a strong absorbance at 1767 cm⁻¹, suggestive of a γ -lactone, and no other carbonyl or hydroxy band. The ¹³C NMR data, together with the results of ¹H NMR (Table 3) and HSQC experiments, indicated the presence of six sp² methine, 11 sp³ methylene, and three methyl groups, two of which appeared as singlets (δ 1.38 and 1.28) and one as a triplet (δ 1.00, *J* = 5.0 Hz) in the ¹H NMR spectrum. The remaining carbons were assigned as a lactone carbonyl (δ 174.3, C), two oxygenated quaternary carbons observed at δ 82.8 and 80.1, and one oxygenated methine carbon at δ 81.1. Analysis of the ¹H-¹H COSY and HSQC spectra of **2** allowed us to establish partial structures which in turn were linked by the ^{2,3}J_{C-H} long-range HMBC correlations and side-by-side comparisons to the spectroscopic data of related peroxide-lactones.⁵ In the HMBC spectrum, H-3 (δ 4.45) was coupled to C-1 (δ 174.3); H₃-23 (δ 1.38) was coupled to C-3 (δ 81.1), C-4 (δ 82.8), and C-5 (δ 40.5); H₃-24 (δ 1.28) was coupled to C-5 (δ 40.5), C-6 (δ 80.1), and C-7 (δ 41.0). While the carbon connectivity about the peroxide-lactone moiety of **2**, established by COSY, HSQC, and HMBC experiments, was found to be identical to that of known plakortolide F (**5**), the relative configuration of the peroxide ring was different. A NOESY spectrum exhibited strong correlation between the H-5 α resonance observed at δ 2.16 and H₃-24 and between the H-5 β signal observed at δ 1.70 and both H₃-23 and H-3, suggesting that the relative configuration of the CH₃-23 and CH₃-24 groups of plakortolide J is *trans*.¹⁰ This contention was supported by the shift differences observed in the ¹³C NMR spectra of peroxide-lactones **2** and **5** for the signals due to the angular methyls at C-6 (δ 22.4 in **2** vs. 24.9 in **5**) and the C-7 methylenes (δ 41.0 in **2** vs. 37.0 in **5**).

The remaining part of the molecule was established to be a conjugated triene along the unbranched C₁₆ alkyl chain on the basis of interpretation of the UV, ¹H NMR, and ¹H-¹H COSY spectra. The position of the triene at ¹⁵, ¹⁷, and ¹⁹ was determined from the COSY, HSQC, and HMBC data. Long-range correlations were observed in the HMBC experiment as follows: the terminal methyl protons observed at δ 1.00 showed coupling to C-21 (δ 25.8) and C-20 (δ 135.9); the allylic protons H₂-21 (δ 2.08) showed coupling to C-19 (δ 129.4), C-20 (δ 135.9) and C-22 (δ 13.6). The ¹H NMR spectrum indicated large *J* values (*J* \approx 14 Hz) for the scalar coupling between H-15 and H-16 and between H-19 and H-20, allowing for the assignment of *E* configuration to the ¹⁵ and ¹⁹ double bonds. The configuration at ¹⁷ was deduced to be *E* as the ¹³C chemical shift values for C-15-C-20

were found to be almost identical to those of conjugated triene **1** in addition to the remarkably similar absorption maxima observed in the UV spectra of **1** and **2**. Moreover, both C-16 and C-19 in **2** would be expected to resonate at higher field (*ca.* 125 ppm) should the double bond at C-17 have the opposite *Z* configuration.^{11,12}

The absolute configuration of **2** was likewise determined upon reductive cleavage of the peroxide–lactone ring with H₂ and 10% Pd/C in EtOAc to afford diol derivative **10** as the main product along with minor peroxide–lactone derivative **11** (Scheme 2). Assignment of the absolute configuration of **10** at C-3 following simple analysis of its ¹³C NMR behavior in CDCl₃ in the presence of chiral lanthanide shift reagents established the absolute configuration of the peroxide ring as 3*S*, 4*S*, 6*S* (Table 2). In a similar manner, we also determined the absolute configuration of plakortolide F (**5**) as 3*S*, 4*S*, 6*R* by reductive cleavage of the peroxide ring in **5** to yield diol–lactone derivative **12** as the sole detectable isomer (Scheme 3) followed by application of Kishi's method.⁹ Furthermore, as the δ value obtained for **12** was arguably low (Table 2), we decided to confirm the latter assignment utilizing the diacetate **13**, which was readily prepared from **12** after treatment with Ac₂O/pyridine. Thus, while the outcomes of these measurements were comparable, insofar as both afforded the same absolute configuration for **5**, we consider that the -0.01 value for δ in these instances is predictive (Table 2).¹³

Epiplakinidioic acid [**3**], (3*S*,5*R*)-3,5-dimethyl-3,5-peroxy-tetradecanedioic acid], C₁₆H₂₈O₆ by HRESIMS, was isolated as a colorless oil that showed a shortened side chain compared to compound **4**. The IR spectrum revealed a broad hydroxy band centered at 3416 cm⁻¹ and a carbonyl band at 1715 cm⁻¹. Inspection of the ¹H and ¹³C NMR (see Experimental Section), COSY, HSQC, and HMBC spectra of **3** indicated the presence of two carboxylic acid units, located at the termini of the 14-carbon spin system starting from C-1. A comparison of the ¹H and ¹³C NMR spectra with those of methyl ester **6** indicated that **3** was the corresponding diacid. All other spectral data, together with the $[\alpha]_D$ value of +33.9 (*c* 1.2, CHCl₃), support the absolute stereostructure assigned to **3**. The observation that compound **4** was also extremely unstable, decomposing rapidly over time, suggests that **3** might be formed during the isolation process upon air-oxidation on the double bond at C-14 of **4**.^{14,15}

Naturally occurring cycloperoxides **1–5**, as well as semisynthetic derivatives **7–12**, were evaluated using MTS assays in DU-145 prostate cancer and melanoma cells in the City of Hope (COH) Comprehensive Cancer Center.¹⁶ Table 4 shows the behavior of these compounds in the DU-145 prostate cancer and A2058 melanoma cells. Fresh samples of **1** and **2**, which might have partially decomposed in transit, were not very active. Aged samples of **1**, which had previously rearranged to **6**, were completely inactive.⁸ On the other hand, the prostate cancer and melanoma cells were significantly more sensitive to compounds **3** and **11**, whereas epiplakininc acid F (**4**) was notably more toxic to the prostate cancer cells. Also, Table 4 shows that semisynthetic derivative **11** was surprisingly potent (less than 1 μ M for the IC₅₀ value) against the melanoma cells. The most abundant natural product, plakortolide F (**5**), was assayed in the NCI's *in vitro* antitumor screen consisting of 60 human tumor cell lines selectively displaying potent cytotoxicity against LOX IMVI

melanoma cancer, IGROV1 ovarian cancer, and UO-30 renal cancer (the percent of growth of the treated cells when compared to the untreated cells was approximately 0, 0, and 17%, respectively). Of the compounds tested for the inhibition of *Plasmodium falciparum*, the parasite responsible for the most severe forms of malaria, compounds **3**, **10** and **11** demonstrated the most toxic effects (IC_{50} 's < 1 $\mu\text{g/mL}$) (Table 4). Interestingly, the *in vitro* antimalarial activity of 1,2-dioxanes **2** and **5** was quite modest compared to that of 1,2-dioxolanes **1** and **4**. When taken together, these results alone cannot account for the strong antimalarial activity shown by **3**, **10** and **11**. *In vitro* antituberculosis screening of compounds **1**, **2**, **4**, **5** and **11** against *Mycobacterium tuberculosis* H₃₇Rv showed moderate to weak inhibitory activity (MIC = 50 $\mu\text{g/mL}$), whereas hydroxy-lactones **9** and **10** significantly inhibited bacterial growth.

Experimental Section

General Experimental Procedures

Optical rotations were obtained with an Autopol IV automatic polarimeter. Infrared and UV spectra were obtained with a Nicolet Magna FT-IR 750 spectrometer and a Shimadzu UV-2401 PC UV-Visible spectrophotometer, respectively. 1D- and 2D-NMR spectra were recorded with a Bruker DRX-500 FT-NMR spectrometer. Mass spectrometric data were generated at the Mass Spectrometry Laboratory of the University of Illinois at Urbana-Champaign. Column chromatography was performed using Si gel (35–75 mesh), and TLC analysis was carried out using glass pre-coated Si gel plates and the spots were visualized using a UV lamp at $\lambda = 254$ nm or by exposure to I₂ vapor. All solvents used were either spectral grade or were distilled from glass prior to use. Commercially available chiral shift reagents (*R*)-Eu(tfc)₃ and (*S*)-Eu(tfc)₃ were purchased from Sigma Aldrich Co. and dried at 130 °C for 48 h prior to use.¹⁷ The percentage yields of compounds **1–5** are based on the weight of the dry sponge specimen. The trivial names assigned to compounds **1–3** are based on previous work by Rinehart and Davidson, respectively.^{4a,5a}

Animal Material

All individuals, found along the ceiling of cave overhangs with a drop-shape, were massively encrusting with irregular conulose surface. Most specimens collected measured up to 20 cm long and 5 cm thick. Color *in situ* was olive green internally and externally with light gray markings on ridges. However, specimens turned into a brownish color when brought to the surface. Individuals were easily broken, with compressible consistency. Noticeable oscules along the surface were circular and measured 2.0–10.0 mm in diameter. The choanosome was compact with many cavities. Both choanosome and ectosome formed by high abundance of diods. However, there were no signs of alveolar arrangement among the diods. The ectosome was darker than the choanosome. Diods were curved with sharp edges. Straight triods with sharp edges were highly abundant. Nonetheless, many triods had rounded edges with a thick center. Triods and diods were variable in size. Minimum diod length varied from 110–160 μm and the maximum actine length of triod length varied between 20–60 μm . The ectosome measured between 450–650 μm thick. A high density of unusual cavities formed a mesh that ran perpendicular to the surface of the ectosome. An

underwater photograph of one of the sponge specimens is available as Supporting Information.

Collection, Extraction, and Isolation

Fresh specimens of the sponge *Plakortis halichondrioides* (Wilson, 1902) (Phylum Porifera; Class Demospongiae; Subclass Homoscleromorpha; Order Homosclerophorida; family Plakinidae) were collected by hand using SCUBA at depths of 90–100 ft off Mona Island, Puerto Rico, in July 2006. A voucher specimen (No. IM06-09) is stored at the Chemistry Department of the University of Puerto Rico, Río Piedras Campus. The organism was frozen and lyophilized prior to extraction. The dry specimens (395 g) were cut into small pieces and blended in a mixture of CHCl_3 –MeOH (1:1) (11 × 1L). After filtration, the crude extract was concentrated and stored under vacuum to yield a dark gum (100 g) that was suspended in H_2O (2L) and extracted with *n*-hexane (3 × 2L). Concentration under reduced pressure yielded 16.4 g of the *n*-hexane extract as a dark brown oil, a portion of which (3.7 g) was chromatographed over Si gel (130 g) using mixtures of *n*-hexane–acetone of increasing polarity (0–100%). A total of 11 fractions (I–XI) were generated on the basis of TLC and ^1H NMR analysis. Further purification of fraction II (1.3 g) by Si gel (20.0 g) column chromatography in 2% acetone–*n*-hexane afforded 8 subfractions denoted as (A–H). Subfraction II(B) consisted of pure epiplakinic acid F methyl ester (**1**) (153.4 mg, 0.17% yield), and subfractions II(F) (47.0 mg) and II(G) (68.3 mg) were pooled together and re-chromatographed over Si gel (8.0 g) in 70% CHCl_3 –*n*-hexane containing several drops of glacial AcOH to yield pure plakortolide J (**2**) (18.6 mg, 0.02% yield). Purification of subfraction II(H) (659.1 mg) by Si gel (13.0 g) column chromatography using CHCl_3 as eluant afforded epiplakinidioic acid (**3**) (4.6 mg, 0.005% yield) along with known epiplakinic acid F (**4**) (16.3 mg, 0.02% yield). Further scrutiny revealed that fraction IV consisted of pure plakortolide F (**5**) (196.3 mg, 0.22% yield).⁷

Methyl (3*S*,5*R*,14*E*,16*E*,18*E*)-3,5-dimethyl-3,5-peroxy-eneicosa-14,16,18-trienoate (epiplakinic acid F methyl ester) (**1**)

pale yellowish oil; $[\alpha]_D^{20} +34.4$ (*c* 1.0, CHCl_3); UV (CH_3OH) λ_{max} (log ϵ) 257 (4.54), 267 (4.66), 278 (4.57) nm; IR (neat) ν_{max} 3013, 2928, 2854, 1740, 1455, 1437, 1375, 1346, 1209, 996 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) and ^{13}C NMR (CDCl_3 , 125 MHz), see Table 1; EIMS m/z [M]⁺ 392 (3), 173 (65), 141 (42), 117 (43), 99 (68), 81 (100), 57 (83), 55 (96); HREIMS m/z [M]⁺ 392.2918 (calcd for $\text{C}_{24}\text{H}_{40}\text{O}_4$, 392.2927).

(3*S*,4*S*,6*S*,15*E*,17*E*,19*E*)-4,6-Dimethyl-4-hydroxy-3,6-peroxy-docosa-15,17,19-trienoic acid 1,4-lactone (plakortolide J) (**2**)

colorless oil; $[\alpha]_D^{20} +29.1$ (*c* 1.1, CHCl_3); UV (CH_3OH) λ_{max} (log ϵ) 258 (4.62), 267 (4.75), 278 (4.67) nm; IR (neat) ν_{max} 3011, 2963, 2924, 2851, 1767, 1456, 1267, 1175, 1159, 993, 916, 725 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz) and ^{13}C NMR (CDCl_3 , 125 MHz), see Table 3; EIMS m/z [M]⁺ 390 (5), 262 (5), 222 (4), 177 (22), 149 (84), 109 (25), 85 (65), 83 (100); HREIMS m/z [M]⁺ 390.2756 (calcd for $\text{C}_{24}\text{H}_{38}\text{O}_4$, 390.2770).

(3S,5R)-3,5-Dimethyl-3,5-peroxy-tetradecanedioic acid (epiplakinidioic acid) (3)

colorless oil; $[\alpha]_D^{20} +33.9$ (*c* 1.2, CHCl₃); IR (neat) ν_{\max} 3416, 2930, 2855, 1715, 1456, 1376, 1306, 1217, 1091, 756 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 2.78 (d, 1H, *J* = 15.0 Hz, H-2 α), 2.71 (d, 1H, *J* = 15.0 Hz, H-2 β), 2.45 (d, 1H, *J* = 12.5 Hz, H-4 β), 2.34 (t, 2H, *J* = 7.5 Hz, H-13 $\alpha\beta$), 2.24 (d, 1H, *J* = 12.5 Hz, H-4 α), 1.70–1.49 (broad m, 4H, H-6 $\alpha\beta$ and H-12 $\alpha\beta$), 1.46 (s, 3H, H₃-15), 1.29 (broad envelope, 13H, H-7-H-11 and H₃-16); ¹³C NMR (CDCl₃, 125 MHz) δ 172.2 (C, C-14), 172.1 (C, C-1), 86.6 (C, C-5), 83.9 (C, C-3), 55.6 (CH₂, C-4), 44.0 (CH₂, C-2), 39.6 (CH₂, C-6), 29.9–28.9 (6 X CH₂, C-8–C-13), 24.4 (CH₂, C-7), 23.9 (CH₃, C-15), 23.2 (CH, C-16); HRESIMS *m/z* [M + Na]⁺ 339.1777 (calcd for C₁₆H₂₈O₆Na, 339.1784).18

Plakortolide F (5)

yellowish oil; $[\alpha]_D^{20} +5.7$ (*c* 1.1, CHCl₃); UV (CH₃OH) λ_{\max} (log ϵ) 224 (3.82), 269 (3.43) nm; IR (neat) ν_{\max} 3417, 2925, 2853, 1763, 1614, 1515, 1464, 1263, 1218, 1172, 955 cm⁻¹. Neither the specific rotation nor the UV data for **5** were previously published. In addition, the original IR spectral data lack some of the key absorption bands described here.4d,7

Spontaneous Decomposition of Epiplakinic Acid F Methyl Ester (1)

Compound **1** was very unstable, decomposing rapidly in CDCl₃ solution in the presence of air and light. Following purification of the decomposition mixture by Si gel column chromatography using 10% EtOAc in hexane as eluant compound **6** was identified as the sole product: colorless oil; $[\alpha]_D^{20} +32.3$ (*c* 1.6, CHCl₃); IR (neat) ν_{\max} 3700–3000 (broad), 2926, 2854, 1732, 1715–1682 (broad), 1456, 1374, 1260, 1091 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 3.69 (s, 3H, –OCH₃), 2.77 (d, 1H, *J* = 14.5 Hz, H-2 α), 2.65 (d, 1H, *J* = 14.5 Hz, H-2 β), 2.47 (d, 1H, *J* = 12.3 Hz, H-4 β), 2.34 (t, 2H, *J* = 7.8 Hz, H-13 $\alpha\beta$), 2.23 (d, 1H, *J* = 12.3 Hz, H-4 α), 1.72–1.48 (broad m, 4H, H-6 $\alpha\beta$ and H-12 $\alpha\beta$), 1.43 (s, 3H, H₃-15), 1.28 (broad envelope, 13H, H-7-H-11 and H₃-16); ¹³C NMR (CDCl₃, 75 MHz) δ 171.1 (2 X C, C-1 and C-14), 86.5 (C, C-5), 83.9 (C, C-3), 55.4 (CH₂, C-4), 51.7 (CH₃, –OCH₃), 44.0 (CH₂, C-2), 39.6 (CH₂, C-6), 30.9 (CH₂, C-13), 29.9–29.4 (5 X CH₂, C-8–C-12), 24.5 (CH₂, C-7), 24.1 (CH₃, C-15), 23.2 (CH₃, C-16); HRESIMS *m/z* [M + Na]⁺ 353.1930 (calcd for C₁₇H₃₀O₆Na, 353.1940).

Reduction of Epiplakinic Acid F Methyl Ester

A mixture of compound **1** (52.8 mg, 0.134 mmol) and 10% Pd on charcoal in EtOAc (15 mL) was stirred under H₂ (1 atm) at 25 °C for 24 h. The reaction mixture was filtered, concentrated *in vacuo*, and the residue obtained was eluted through a short plug of Si gel (1.0 g) with 100% CHCl₃ affording two fractions. The least polar fraction (23.9 mg) was purified further by flash CC over Si gel (0.7 g) using a 9:1 mixture of hexane–EtOAc to afford peroxide-ester derivative **7** (3.8 mg, 7%): yellow oil; $[\alpha]_D^{20} +36.0$ (*c* 0.8, CHCl₃); IR (neat) ν_{\max} 2917, 2849, 1738, 1463, 1375, 1220, 1163, 1097, 1011 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 3.69 (s, 3H, –OCH₃), 2.76 (d, 1H, *J* = 15.0 Hz, H-2 α), 2.65 (d, 1H, *J* = 15.0 Hz, H-2 β), 2.46 (d, 1H, *J* = 15.0 Hz, H-4 β), 2.22 (d, 1H, *J* = 15.0 Hz, H-4 α), 1.59 (broad m, 2H, H-6 $\alpha\beta$), 1.43 (s, 3H, H₃-22), 1.28 (s, 3H, H₃-23), 1.25 (broad envelope, 28H), 0.88 (t, 3H, *J* = 5.0 Hz, H₃-21); ¹³C NMR (CDCl₃, 125 MHz) δ 171.1 (C, C-1), 86.5 (C, C-5), 83.9 (C,

C-3), 55.4 (CH₂, C-4), 51.8 (CH₃, -OCH₃), 44.0 (CH₂, C-2), 39.7 (CH₂, C-6), 31.9 (CH₂, C-19), 30.1 (CH₂, C-7), 29.7–29.4 (11 X CH₂, C-8–C-18), 24.2 (CH₃, C-22), 23.3 (CH₃, C-23), 22.7 (CH₂, C-20), 14.1 (CH₃, C-21); ESIMS *m/z* [M + H]⁺ 399.3 (calcd for C₂₄H₄₇O₄, 399.3). The more polar fraction was identified as diol-ester derivative **8** (15.4 mg, 29%): colorless oil; [α]_D²⁰ +8.9 (*c* 1.4, CHCl₃); IR (neat) *v*_{max} 3400, 2920, 2851, 1738, 1467, 1439, 1377, 1342, 1206, 1013 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 3.71 (s, 3H, -OCH₃), 2.83 (d, 1H, *J* = 15.0 Hz, H-2α), 2.50 (d, 1H, *J* = 15.0 Hz, H-2β), 1.80 (d, 1H, *J* = 15.0 Hz, H-4β), 1.70 (d, 1H, *J* = 15.0 Hz, H-4α), 1.52 (broad m, 2H, H-6αβ), 1.35 (s, 3H, H₃-22), 1.27 (s, 3H, H₃-23), 1.25 (broad envelope, 28H), 0.87 (t, 3H, *J* = 5.0 Hz, H-21); ¹³C NMR (CDCl₃, 125 MHz) δ 173.4 (C, C-1), 73.4 (C, C-5), 72.3 (C, C-3), 51.7 (CH₃, -OCH₃), 49.0 (CH₂, C-4), 46.1 (CH₂, C-2), 44.8 (CH₂, C-6), 31.9 (CH₂, C-19), 30.2 (CH₂, C-7), 29.7–29.3 (11 X CH₂, C-8–C-18), 29.6 (CH₃, C-22), 28.8 (CH₃, C-23), 22.7 (CH₂, C-20), 14.1 (CH₃, C-21); ESIMS *m/z* [M + H]⁺ 401.3 (calcd for C₂₄H₄₉O₄, 401.3).

Synthesis of δ-Lactone **9**

A solution of diol-ester derivative **8** (15.4 mg, 0.038 mmol) in hexane (15 mL) was treated with glacial acetic acid (3 drops) and heated to 60 °C for 2 h. Evaporation *in vacuo* afforded pure δ-lactone **9** (8.0 mg, 56%): white solid; [α]_D²⁰ +14.6 (*c* 1.0, CHCl₃); IR (neat) *v*_{max} 3470, 2920, 2851, 1703, 1468, 1379, 1145, 1115, 1036, 800 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 2.63 (dd, 1H, *J* = 16.5, 2.0 Hz, H-2α), 2.51 (d, 1H, *J* = 16.5 Hz, H-2β), 2.08 (dd, 1H, *J* = 14.5, 2.0 Hz, H-4α), 1.73 (d, 1H, *J* = 14.5 Hz, H-4β), 1.80 (br m, 2H, H₂-6), 1.41 (s, 6H, H₃-22 and H₃-23), 1.30–1.20 (broad envelope, 28H), 0.89 (t, 3H, *J* = 6.5 Hz, H₃-21); ¹³C NMR (CDCl₃, 125 MHz) δ 170.3 (C, C-1), 83.7 (C, C-5), 69.3 (C, C-3), 45.1 (CH₂, C-4), 43.9 (CH₂, C-2), 42.5 (CH₂, C-6), 31.9 (CH₂, C-7), 30.9 (CH₃, C-23), 29.9–29.3 (11 X CH₂, C-8–C-18), 28.9 (CH₃, C-22), 24.1 (CH₂, C-19), 22.7 (CH₂, C-20), 14.1 (CH₃, C-21); EIMS *m/z* [M-H₂O]⁺ 350 (4), 335 (3), 290 (4), 266 (10), 143 (100), 125 (52), 103 (45), 101 (90), 85 (15), 83 (20).

Reduction of Plakortolide **J** (**2**)

A mixture of plakortolide **J** (28.0 mg, 0.071 mmol) and 10% Pd on charcoal in EtOAc (15 mL) was stirred under H₂ (1 atm) at 25 °C for 24 h. The reaction mixture was filtered and concentrated *in vacuo* to afford an oil that was chromatographed through a short plug of Si gel (0.8 g) using a 4:1 mixture of CHCl₃–EtOAc as eluant thus providing pure **10** and **11**; compound **10** (14.0 mg, 49%): white solid; [α]_D²⁰ +3.7 (*c* 0.8, CHCl₃); IR (neat) *v*_{max} 3487, 3345, 2915, 2850, 1767, 1470, 1379, 1292, 1201, 1170, 1070, 941 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 4.20 (d, 1H, *J* = 10.0 Hz, H-3), 2.92 (dd, 1H, *J* = 20.0, 10.0 Hz, H-2β), 2.55 (d, 1H, *J* = 20.0 Hz, H-2α), 2.17 (d, 1H, *J* = 15.0 Hz, H-5α), 2.09 (d, 1H, *J* = 15.0 Hz, H-5β), 1.60 (broad m, 2H, H-7αβ), 1.44 (s, 3H, H₃-23), 1.35 (s, 3H, H₃-24), 1.28–1.25 (broad envelope, 28H), 0.88 (t, 3H, *J* = 5.0 Hz, H₃-22); ¹³C NMR (CDCl₃, 125 MHz) δ 175.3 (C, C-1), 90.1 (C, C-4), 73.8 (CH, C-3), 73.0 (C, C-6), 43.9 (CH₂, C-5), 43.6 (CH₂, C-7), 38.1 (CH₂, C-2), 31.9 (CH₂, C-20), 30.0 (CH₃, C-24), 29.7–29.3 (11 X CH₂, C-9–C-19), 26.8 (CH₃, C-23), 24.4 (CH₂, C-8), 22.7 (CH₂, C-21), 14.1 (CH₃, C-22); EIMS *m/z* [M-H₂O-CH₃]⁺ 365 (3), 309 (17), 292 (5), 269 (14), 173 (38), 155 (87), 130 (13), 113 (100), 95 (19), 71 (26); HRESIMS *m/z* [M + H]⁺ 399.3483 (calcd for C₂₄H₄₇O₄, 399.3474); compound **11**

(5.0 mg, 18%): white solid; $[\alpha]_D^{20} +27.5$ (*c* 1.2, CHCl₃); IR (film) ν_{\max} 2920, 2851, 1769, 1468, 1379, 1268, 1176, 1080, 1057, 954, 917 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 4.46 (d, 1H, *J* = 5.0 Hz, H-3), 2.91 (dd, 1H, *J* = 20.0, 5.0 Hz, H-2 β), 2.62 (d, 1H, *J* = 20.0 Hz, H-2 α), 2.16 (d, 1H, *J* = 15.0 Hz, H-5 α), 1.70 (d, 1H, *J* = 15.0 Hz, H-5 β), 1.51 (m, 2H, H-7 $\alpha\beta$), 1.39 (s, 3H, H₃-23), 1.28 (s, 3H, H₃-24), 1.25 (broad envelope, 28H), 0.88 (t, 3H, *J* = 5.0 Hz, H₃-22); ¹³C NMR (CDCl₃, 125 MHz) δ 174.3 (C, C-1), 82.8 (C, C-4), 81.1 (CH, C-3), 80.1 (C, C-6), 41.0 (CH₂, C-7), 40.5 (CH₂, C-5), 34.3 (CH₂, C-2), 31.9 (CH₂, C-20), 30.0 (CH₂, C-8), 29.7–29.4 (11 X CH₂, C-9–C-19), 25.9 (CH₃, C-23), 23.1 (CH₂, C-21), 22.7 (CH₃, C-24), 14.1 (CH₃, C-22); EIMS *m/z* [M–C₁₆H₃₃]⁺ 171 (50), 155 (48), 101 (42), 85 (68), 83 (100), 71 (88); HRESIMS *m/z* [M + H]⁺ 397.3316 (calcd for C₂₄H₄₅O₄, 397.3318).

Reduction of Plakortolide F (5)

A mixture of plakortolide F (70.0 mg, 0.179 mmol) and 10% Pd on charcoal in EtOAc (15 mL) was stirred under H₂ (1 atm) at 25 °C for 24 h. The reaction mixture was filtered and concentrated *in vacuo* to afford a homogeneous oil that was passed through a short plug of Si gel (1.0 g) using a 4.5:0.5 mixture of CHCl₃–EtOAc to obtain diol–lactone derivative **12** (17.4 mg, 25%): white solid; $[\alpha]_D^{20} +31$ (*c* 0.2, CHCl₃); UV (CH₃OH) (log ϵ) λ_{\max} 224 (4.16), 279 (3.56) nm; IR (neat) ν_{\max} 3381, 2918, 2848, 1729, 1615, 1518, 1465, 1384, 1249, 1200, 1077, 934 cm⁻¹; ¹H NMR (acetone-*d*₆, 500 MHz) δ 7.00 (d, 2H, *J* = 5.0 Hz, H-17), 6.72 (d, 2H, *J* = 5.0 Hz, H-18), 5.05 (broad s, 1H, exchangeable, 3-OH), 4.39 (broad s, 1H, exchangeable, 6-OH), 4.22 (d, 1H, *J* = 10.0 Hz, H-3), 2.98 (dd, 1H, *J* = 20.0, 5.0 Hz, H-2 β), 2.49 (t, 2H, *J* = 5.0 Hz, H-15 $\alpha\beta$), 2.25 (d, 1H, *J* = 20.0 Hz, H-2 α), 2.22 (d, 1H, *J* = 15.0 Hz, H-5 α), 1.85 (d, 1H, *J* = 15.0 Hz, H-5 β), 1.56–1.53 (broad m, 4H, H-7 α , H-8 α , H-14 $\alpha\beta$), 1.47 (s, 3H, H₃-20), 1.40 (broad m, 2H, H-7 β , H-8 β), 1.35 (s, 3H, H₃-21), 1.30–1.28 (broad envelope, 10H); ¹³C NMR (acetone-*d*₆, 125 MHz) δ 175.0 (C, C-1), 156.0 (C, C-19), 134.1 (C, C-16), 129.8 (2 X CH, C-17), 115.7 (2 X CH, C-18), 90.6 (C, C-4), 74.0 (CH, C-3), 72.0 (C, C-6), 47.0 (CH₂, C-7), 45.2 (CH₂, C-5), 38.2 (CH₂, C-2), 35.5 (CH₂, C-15), 32.5 (CH₂, C-14), 30.8 (CH₂, C-13), 29.0 (4 X CH₂, C-9–C-12), 27.9 (CH₃, C-20), 25.5 (CH₃, C-21), 24.4 (CH₂, C-8); EIMS *m/z* [M–C₁₅H₂₃O]⁺ 173 (6), 155 (100), 113 (20), 107 (98); ESIMS *m/z* [M + Li]⁺ 399.3 (calcd for C₂₃H₃₆O₅Li, 399.3).

Acetylation of Diol–lactone Derivative 12

A mixture of diol–lactone **12** (40.0 mg, 0.102 mmol), dry pyridine (2.0 mL), and acetic anhydride (0.2 mL) was stirred at 25 °C for 24 h. The reaction mixture was concentrated *in vacuo* and the oily residue obtained was passed through a short plug of Si gel (0.7 g) using a 7:3 mixture of *n*-hexane–acetone to afford diacetate **13** (38 mg, 95%): yellowish oil; $[\alpha]_D^{20} +8.2$ (*c* 1.2, CHCl₃); UV (CH₃OH) (log ϵ) λ_{\max} 202 (3.78), 265 (2.58), 271 (2.55) nm; IR (neat) ν_{\max} 3516, 2926, 2854, 1747, 1508, 1464, 1372, 1234, 1046, 944, 913 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 7.16 (d, 2H, *J* = 5.0 Hz, H-17), 6.97 (d, 2H, *J* = 5.0 Hz, H-18), 5.18 (d, 1H, *J* = 10.0 Hz, H-3), 3.03 (dd, 1H, *J* = 20.0, 5.0 Hz, H-2 β), 2.57 (t, 2H, *J* = 5.0 Hz, H-15 $\alpha\beta$), 2.45 (d, 1H, *J* = 20.0 Hz, H-2 α), 2.27 (s, 3H, OCOCH₃), 2.09 (s, 3H, OCOCH₃), 1.92 (dd, 2H, *J* = 20.0, 15.0 Hz, H-5 $\alpha\beta$), 1.58 (s, 3H, H₃-20), 1.47 (m, 2H, H-7 $\alpha\beta$), 1.31 (s, 3H, H₃-21), 1.29–1.25 (broad envelope, 14H); ¹³C NMR (CDCl₃, 125 MHz) δ 173.7 (C, C-1), 169.8 (C, OCOCH₃), 169.6 (C, OCOCH₃), 148.5 (C, C-19), 140.4

(C, C-16), 129.2 (2 X CH, C-17), 121.1 (2 X CH, C-18), 88.1 (C, C-4), 75.8 (CH, C-3), 72.2 (C, C-6), 45.8 (CH₂, C-7), 43.2 (CH₂, C-5), 35.7 (CH₂, C-2), 35.3 (CH₂, C-15), 31.4 (CH₂, C-14), 30.0 (CH₂, C-13), 29.6–29.2 (4 X CH₂, C-9–C-12), 27.9 (CH₃, C-20), 24.6 (CH₃, C-21), 23.7 (CH₂, C-8), 21.1 (CH₃, OCOCH₃), 20.9 (CH₃, OCOCH₃); ESIMS m/z [M–H₂O + Na]⁺ 481.3 (calcd for C₂₇H₃₈O₆Na, 481.3) and m/z [M–H₂O+H]⁺ 459.3 (calcd for C₂₇H₃₉O₆, 459.3).

Determination of Absolute Configuration of Alcohols **9**, **10**, **12**, and **13**

Samples were prepared individually in an oven-dried vial with ~ 3.5–4.5 mg of alcohols **9**, **10**, **12**, and **13** in 0.5 mL of C₆D₆, CDCl₃, acetone-*d*₆, and CDCl₃, respectively, containing 15% per OH of chiral shift reagent. The samples were transferred to oven-dried NMR tubes (cooled to room temperature under a stream of nitrogen) via syringe.¹⁷ Following acquisition, each substrate was recovered by filtration through a pipette column of Si gel (Sep-Pak Si gel cartridge). For each filtration CH₂Cl₂ was used as the solvent. To determine the absolute configuration of the alcohols in **9**, **10**, **12**, and **13** according to a method described by Kishi and coworkers, the NMR behaviors of the carbons adjacent to the alcoholic center (CX and CY) were measured in the presence of (*R*)- and (*S*)-Eu(tfc)₃ (see Table 2).^{9,19}

Cytotoxicity Assay

DU-145 human prostate cancer, A2058 melanoma, and MDA-MB-435 breast cancer cell lines were obtained from ATCC. These cells were cultured in RPMI-1640 or DMEM medium containing 10% fetal bovine serum (FBS), 100 units/mL of penicillin, and 100 µg/mL streptomycin. All cells were maintained in a 5% CO₂ atmosphere at 37 °C. To determine the viability of the cells, Promega CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assays (MTS) were performed as described by the supplier (Promega; Madison, WI).²⁰ Briefly, cells (5,000/well) were seeded in 96-well plates and incubated overnight at 37 °C in 5% CO₂. Cells were treated for 48 h with each compound. The concentration used was 10 µM. Dimethyl sulfoxide (DMSO) was used as the vehicle control. IC₅₀ values of compounds were determined in a dose-dependent manner (0.1, 0.5, 1, 5, 10, 20, and 50 µM). Cell viability was determined by tetrazolium conversion to its formazan dye and absorbance of formazan was measured at 490 nm using an automated ELISA plate reader. The production of formazan dye was directly proportional to the number of living cells. Each experiment was done in quadruplicate in the absence of a positive control.

Antituberculosis and Antiplasmodial Assays

Biological activity tests against the pathogenic microbes *Mycobacterium tuberculosis* and *Plasmodium falciparum* were performed as previously described.²¹ Rifampin and chloroquine were used as positive controls, respectively.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.



Acknowledgments

We thank J. Marrero, J.C. Asencio, R. Rios, J.J. La Clair, M.J. Lear, and the crew of the R/V Pez Mar for providing logistic support during the sponge collection. The National Cancer Institute (NCI), the Institute for Tuberculosis Research at the University of Illinois at Chicago, and the INDICASAT (Clayton, Panama) provided *in vitro* cytotoxicity, antituberculosis, and antimalarial activity data, respectively. Mass spectral determinations were provided by the Mass Spectrometry Laboratory of the University of Illinois at Urbana-Champaign. The expert assistance of Dr. V. Vicente for sponge taxonomy determination is gratefully acknowledged. Financial support to C. J. -Romero was provided by the IFARHU-SENACYT Program of the Republic of Panama. This work was supported by a grant from the NIH-SC1 Program (Grant 1SC1GM086271-01A1) awarded to A.D.R.

References and Notes


- (1). (a) Casteel DA. *Nat. Prod. Rep.* 1992; 9:289–312. [PubMed: 1522977] (b) Casteel DA. *Nat. Prod. Rep.* 1999; 16:55–73. (c) Rahm F, Hayes PY, Kitching W. *Heterocycles.* 2004; 64:523–575. (d) Dembitsky VM, Glorizova TA, Poroikov VV. *Mini-Rev. Med. Chem.* 2007; 7:571–589. [PubMed: 17584156] (d)
- (2). (a) Tagliatalata-Scafati O, Fattorusso E, Romano A, Scala F, Barone V, Cimino P, Stendardo E, Catalanotti B, Persico M, Fattorusso C. *Org. Biomol. Chem.* 2010; 8:846–856. [PubMed: 20135043] (b) Feng Y, Davis RA, Sykes M, Avery VM, Camp D, Quinn RJ. *J. Nat. Prod.* 2010; 73:716–719. [PubMed: 20235550] (c) Kossuga MH, Nascimento AM, Reimão JQ, Tempone AG, Taniwaki NN, Veloso K, Ferreira AG, Cavalcanti BC, Pessoa C, Moraes MO, Mayer AMS, Hajdu E, Berlinck RGS. *J. Nat. Prod.* 2008; 71:334–339. [PubMed: 18177008]
- (3). Blunt JW, Copp BR, Munro MHG, Northcote PT, Prinsep MR. *Nat. Prod. Rep.* 2010; 27:165–237. [PubMed: 20111802] and previous articles in this series.
- (4). (a) Phillipson DW, Rinehart KL Jr. *J. Am. Chem. Soc.* 1983; 105:7735–7736. (b) Davidson BS. *J. Org. Chem.* 1991; 56:6722–6724. (c) Horton PA, Longley RE, Kelly-Borges M, McConnell OJ, Ballas LM. *J. Nat. Prod.* 1994; 57:1374–1381. [PubMed: 7807122] (d) Chen Y, Killday KB, McCarthy PJ, Schimoler R, Chilson K, Selitrennikoff C, Pomponi SA, Wright AE. *J. Nat. Prod.* 2001; 64:262–264. [PubMed: 11430018] (e) Dalisay DS, Quach T, Molinski TF. *Org. Lett.* 2010; 12:1524–1527. [PubMed: 20205426]
- (5). (a) Davidson BS. *Tetrahedron Lett.* 1991; 32:7167–7170. (b) Varoglu M, Peters BM, Crews P. *J. Nat. Prod.* 1995; 58:27–36. [PubMed: 7760075] (c) Qureshi A, Salvá J, Harper MK, Faulkner DJ. *J. Nat. Prod.* 1998; 61:1539–1542. [PubMed: 9868160] (d) Perry TL, Dickerson A, Khan AA, Kondru RK, Beratan DN, Wipf P, Kelly M, Hamann MT. *Tetrahedron.* 2001; 57:1483–1487. (e) Rudi A, Afanii R, Gravalos LG, Aknin M, Gaydou E, Vacelet J, Kashman Y. *J. Nat. Prod.* 2003; 66:682–685. [PubMed: 12762807]
- (6). (a) del Sol Jiménez M, Garzón SP, Rodríguez AD. *J. Nat. Prod.* 2003; 66:655–661. [PubMed: 12762801] (b) del Sol Jiménez M, Garzón SP, Rodríguez AD. *J. Nat. Prod.* 2003; 66:1404.
- (7). The trivial name plakortolide F was claimed simultaneously by Hamann (ref. 5d) and Wright (ref. 4d) for two peroxide–lactones isolated from distinct *Plakinastrella* sponge species. The compound herein referred to as plakortolide F (*i.e.* 5) was identical to the material reported by the Wright group.
- (8). Compound 6 showed no cytotoxicity against DU-145 prostate cancer or A2058 melanoma cells at a concentration of 10 μ M, nor was it active against *Mycobacterium tuberculosis* H₃₇Rv at concentrations 64 μ g/mL.
- (9). (a) Ghosh I, Zeng H, Kishi Y. *Org. Lett.* 2004; 6:4715–4718. [PubMed: 15575668] (b) Adams CM, Ghosh I, Kishi Y. *Org. Lett.* 2004; 6:4723–4726. [PubMed: 15575670]
- (10). For related peroxide–lactones having *trans* methyl substituents at the C-4 and C-6 positions, see refs. 5b and 5d.
- (11). Yasuda I, Takeya K, Itokawa H. *Phytochemistry.* 1982; 21:1295–1298.
- (12). Guella G, Mancini I, Pietra F. *Helv. Chim. Acta.* 1989; 72:1121–1124.
- (13). The lowest value for δ in the article by Kishi and coworkers (ref. 9a) is -0.029 .

- (14). The conjugated polyene chain of compounds **1**, **2** and **4** is a reactive, electron-rich system that is likely susceptible to attack by electrophilic reagents such as hydroxy and peroxy radicals, and thus is responsible for the instability of these compounds towards oxidation. `
- (15). Given their extreme chemical instability, we speculate that Nature uses unsaturated conjugated polyenes such as **1**, **2** and **4** as biogenetic precursors to the phenyl polyketide peroxide series of *Plakortis/Plakinastrella* metabolites (i.e. the plakortolides) via a cascade of efficient *E/Z*-isomerizations, electrocyclizations, and further dehydrogenations to account for aromatic ring formation. For articles suggesting that some of these conversions are chemically viable, see: Jacobsen MF, Moses JE, Adlington RM, Baldwin JE. *Tetrahedron*. 2006; 62:1675–1689. Rodríguez R, Adlington RM, Eade SJ, Walter MW, Baldwin JE, Moses JE. *Tetrahedron*. 2007; 63:4500–4509.
- (16). Wright and coworkers reported that free acid **4** showed moderate antifungal activity against *Candida albicans*, whereas **5** was inactive against both *C. albicans* and *Aspergillus fumigatus*; see: ref. 4d.
- (17). In order to obtain reliable results, it is essential that both (*R*)- and (*S*)-enantiomers of the shift reagent be of similar quality (purity and moisture content), and that NMR data with both the (*R*)- and (*S*)-shift reagent be collected on the same instrument.
- (18). The ¹³C NMR chemical shifts assigned to the carbonyl carbons of **3** are not very accurate as these signals were weak and broad. The assignments shown can be interchanged.
- (19). It has been noted that δ are always greater with chiral Pr-based shift reagents than with the corresponding Eu-based shift reagents. Thus, the former lanthanide shift reagents have a superior capacity for enantiotopic discrimination of carbons within a molecule; see: ref. 9a.
- (20). (a) Malich G, Markovic B, Winder C. *Toxicology*. 1997; 124:179–192. [PubMed: 9482120] (b) Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R. *Mol. Cancer Ther.* 2007; 6:1400–1405. [PubMed: 17431118]
- (21). Wei X, Rodríguez AD, Baran P, Raptis RG. *J. Nat. Prod.* 2010; 73:925–934. [PubMed: 20384296]




i. H₂, 10% Pd/C in EtOAc, 25 °C, 20 h (36%); ii. AcOH in hexane, 60 °C, 2 h (56%).

Scheme 1.
Conversion of endoperoxide **1** to derivatives **7–9**.

**Scheme 2.**

Conversion of plakortolide J (**2**) to lactones **10** and **11**.

**Scheme 3.**

Conversions of plakortolide F (5) to diol-lactone derivative 12 and diacetate 13.

Table 1

^{13}C NMR (125 MHz), ^1H NMR (500 MHz), HMBC and NOESY Spectroscopic Data for Epiplakinic Acid F Methyl Ester (**1**) in CDCl_3^a

atom	δ_{C} , mult ^b	δ_{H} , mult (J in Hz)	HMBC ^c	NOESY
1	171.1, C			
2 α	44.0, CH ₂	2.76, d (14.5)	1, 3, 4, 22	H-4 β , H ₃ -22
2 β		2.65, d (14.5)	1, 3, 4, 22	H-4 β , H ₃ -22
3	83.9, C			
4 α	55.4, CH ₂	2.22, d (12.5)	2, 5, 6, 7, 22	H-6 $\alpha\beta$, H ₃ -22
4 β		2.46, d (12.5)	2, 5, 6, 23	H-2 $\alpha\beta$, H ₃ -23
5	86.5, C			
6 α	39.6, CH ₂	1.69, br t (12.2)		H-4 α
6 β		1.53, br t (12.2)		H-4 α
7 α	24.5, CH ₂	1.28, br s		
7 β		1.37, br m		
8	29.5, CH ₂	1.28, br s		
9	29.4, CH ₂	1.28, br s		
10	29.3, CH ₂	1.28, br s		
11	30.0, CH ₂	1.28, br s		
12	29.1, CH ₂	1.37, br m		10
13	32.8, CH ₂	2.05, m	12, 14, 15	
14	134.5, CH	5.65, dt (14.2, 7.0)	13, 16	
15	130.4, CH	6.03, br m	16	
16	130.9, CH	6.10, br m	18	
17	130.8, CH	6.08, br m	18	
18	129.5, CH	6.06, br m	17	
19	135.9, CH	5.71, dt (14.5, 7.5)	17, 20, 21	
20	25.8, CH ₂	2.08, m	18, 19, 21	
21	13.6, CH ₃	0.99, t (7.4)	19, 20	
22	24.1, CH ₃	1.43, s	2, 3, 4	H-2 $\alpha\beta$, H-4 α
23	23.3, CH ₃	1.28, s	4, 5, 6, 7	H-4 β
-OCH ₃	51.7, CH ₃	3.69, s	1	

^aChemical shift values are in parts per million relative to the residual CHCl_3 (7.26 ppm) or CDCl_3 (77.0 ppm) signals. Assignments were aided by 2D NMR experiments, spin-splitting patterns, number of attached protons, and chemical shift values.

^b ^{13}C NMR multiplicities were obtained from a DEPT-135 experiment.

^cCarbon atoms correlated to proton resonances in the ^1H column. Parameters were optimized for $^{2,3}J_{\text{C-H}} = 6$ and 8 Hz.

Table 2

Assignment of Absolute Configuration of Compounds **9**, **10**, **12**, and **13** at 15 mol % per OH of (*R*)- and (*S*)-Eu(tfc)₃ and Empirical Rules for the Determination of Absolute Configuration of Secondary and Tertiary Alcohols^a

Compound	$\delta_R = \delta_{CX_R} - \delta_{CY_R}$		$\delta_S = \delta_{CX_S} - \delta_{CY_S}$		$\delta = \delta_R - \delta_S$		
	δ_{CX_R}	δ_{CY_R}	δ_{CX_S}	δ_{CY_S}			
9	44.16	44.73	-0.57	44.23	44.75	-0.52	-0.05
10	90.41	38.87	51.54	90.32	38.73	51.59	-0.05
12	90.53	38.15	52.38	90.53	38.14	52.39	-0.01
13	46.01	43.39	2.62	45.97	43.34	2.63	-0.01

α -orientation
 $\Delta\Delta\delta = \text{negative}$

β -orientation
 $\Delta\Delta\delta = \text{positive}$

9

10 and 12

13

$$\Delta\Delta\delta = \delta_{CX_{(R)\text{-Eu(tfc)}_3}} - \delta_{CY_{(S)\text{-Eu(tfc)}_3}}$$

$$\Delta\delta_{(R)\text{-Eu(tfc)}_3} = \delta_{CX_{(R)\text{-Eu(tfc)}_3}} - \delta_{CY_{(R)\text{-Eu(tfc)}_3}}$$

$$\Delta\delta_{(S)\text{-Eu(tfc)}_3} = \delta_{CX_{(S)\text{-Eu(tfc)}_3}} - \delta_{CY_{(S)\text{-Eu(tfc)}_3}}$$

^aThe ¹³C NMR data of alcohols **9**, **10**, **12**, and **13** were recorded in C₆D₆, CDCl₃, acetone-*d*₆, and CDCl₃, respectively.

Table 3

^{13}C NMR (125 MHz), ^1H NMR (500 MHz), HMBC and NOESY Spectroscopic Data for Plakortolide J (**2**) in CDCl_3^a

atom	δ_{C} , mult ^b	δ_{H} , mult (J in Hz)	HMBC ^c	NOESY
1	174.3, C			
2 α	34.3, CH ₂	2.62, d (15.0)	1, 3	H-2 β
2 β		2.91, dd (15.0, 10.0)	1, 3	H-2 α , H ₃ -23
3	81.1, CH	4.45, d (10.0)	1, 2, 3	H-5 β , H ₃ -23
4	82.8, C ^d			
5 α	40.5, CH ₂	2.16, d (15.0)	3, 4, 23, 24	H-5 β , H ₃ -24
5 β		1.70, d (15.0)	6, 7, 23, 24	H-3, H-5 α , H-7 $\alpha\beta$, H ₃ -23
6	80.1, C			
7 α	41.0, CH ₂	1.50, br m		
7 β		1.50, br m		
8	23.1, CH ₂	1.37, br m		
9	29.5, CH ₂	1.27, br m		
10	29.4, CH ₂	1.27, br s		
11	29.3, CH ₂	1.27, br s		
12	30.0, CH ₂	1.27, br m		
13	29.1, CH ₂	1.37, br m		
14	32.8, CH ₂	2.06, br m	13, 15, 16	
15	134.4, CH	5.65, dt (14.2, 7.0)	14, 17	
16	130.4, CH	6.04, br m	17	
17	130.9, CH	6.10, br m	19	
18	130.8, CH	6.07, br m	19	
19	129.4, CH	6.02, br m	18	
20	135.9, CH	5.71, dt (14.5, 7.5)	18, 21, 22	
21	25.8, CH ₂	2.08, m	19, 20, 22	
22	13.6, CH ₃	1.00, t (5.0)	20, 21	
23	25.9, CH ₃	1.38, s	3, 4, 5	H-2 β , H-3, H-5 β
24	22.4, CH ₃	1.28, s	5, 6, 7	H-5 α

^aChemical shift values are in parts per million relative to the residual CHCl_3 (7.26 ppm) or CDCl_3 (77.0 ppm) signals. Assignments were aided by 2D NMR experiments, spin-splitting patterns, number of attached protons, and chemical shift values.

^b ^{13}C NMR multiplicities were obtained from a DEPT-135 NMR experiment.

^cCarbon atoms correlated to proton resonances in the ^1H column. Parameters were optimized for $^{2,3}J_{\text{CH}} = 6$ and 8 Hz.

^dBroad resonance line of low intensity.

Table 4

Biological Activities of Compounds 1–5 and 7–12

Compound	Cancer cell line			Infectious microorganism			
	DU-145	A2058	(% Growth) ^a (IC ₅₀ μM) ^b	DU-145	A2058	<i>P. falciparum</i> ^c	<i>M. tuberculosis</i> ^d
1	92	86	>10	>10	>10	4	62
2	112	106	>10	>10	>10	>10	71
3	31	23	4	3	0.3	0.3	N.T. ^e
4	15	51	1	>10	>10	3	92
5	62	71	>10	>10	>10	>10	59
7	38	69	8	>10	>10	>10	N.T. ^e
8	81	79	>10	>10	>10	>10	N.T. ^e
9	102	60	>10	>10	>10	>10	30
10	79	75	24	24	0.6	0.6	13
11	13	8	2	0.8	0.3	0.3	68
12	95	81	>10	>10	>10	7	N.T. ^e
+Ctrl	–	–	–	–	–	0.09	0.05

^a DU-145 prostate cancer and A2058 melanoma cells (5,000 cells/well, 96 well plates) were treated with compounds at 10 μM for 48 h.

^b Cells were treated with compounds in a dose-dependent manner for 48 h. Then, the MTS assays assessed cell viability. Experiments in quadruplicate.

^c Chloroquine-resistant (CQ-R) W2 strains. IC₅₀ in μg/mL. Chloroquine was used as a positive control.

^d *Mtb* H37Rv strain. Minimum inhibitory concentrations (MIC) in μg/mL. Rifampin was used as a positive control.

^e N.T. = Not tested.